Get the Stockscreener App
15.60
1.70%
-0.27
After Hours:
15.53
-0.07
-0.45%
Vor Biopharma Inc stock is traded at $15.60, with a volume of 880.42K.
It is down -1.70% in the last 24 hours and up +15.47% over the past month.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
See More
Previous Close:
$15.87
Open:
$16.09
24h Volume:
880.42K
Relative Volume:
0.89
Market Cap:
$762.02M
Revenue:
-
Net Income/Loss:
$-695.98M
P/E Ratio:
-0.0475
EPS:
-328.6331
Net Cash Flow:
$-143.65M
1W Performance:
-0.92%
1M Performance:
+15.47%
6M Performance:
-48.38%
1Y Performance:
+11.43%
1-Day Range:
$15.41
$16.15
1-Week Range:
$15.20
$16.55
52-Week Range:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
15.60 | 775.21M | 0 | -695.98M | -143.65M | -328.63 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Jefferies | Buy |
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Dec-17-25 | Initiated | TD Cowen | Buy |
| Dec-09-25 | Initiated | JP Morgan | Overweight |
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Ra Capital Management, L.P. Sells 530,610 Shares of Vor Biopharma (NASDAQ:VOR) Stock - MarketBeat
RA Capital sells Vor Biopharma (VOR) shares worth $11.8 million - Investing.com
Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 153,735 Shares of Stock - MarketBeat
Vor Biopharma (NASDAQ:VOR) Director Sells $858,840.44 in Stock - MarketBeat
H.C. Wainwright lowers Vor Biopharma price target to $31 By Investing.com - Investing.com Australia
HC Wainwright Has Lowered Expectations for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
VOR Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $31 - GuruFocus
Vor Biopharma, Inc. (VOR) PT Lowered to $31 at H.C. Wainwright - StreetInsider
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Up 66.5% in March - MarketBeat
Vor Biopharma(VOR.US) 10% Shareholder Sells US$10.23 Million in Common Stock - Moomoo
Ra capital sells Vor Biopharma (VOR) shares worth $10.2 million By Investing.com - Investing.com India
Vor Biopharma (NASDAQ:VOR) Director Sells $2,242,984.59 in Stock - MarketBeat
Ra Capital Management, L.P. Sells 484,104 Shares of Vor Biopharma (NASDAQ:VOR) Stock - MarketBeat
Vor Biopharma (NASDAQ:VOR) Director Sells $13,041.00 in Stock - MarketBeat
Ra capital sells Vor Biopharma (VOR) shares worth $10.2 million - Investing.com
RA Capital trims Vor Biopharma (VOR) stake while keeping 19.9% ownership - Stock Titan
RA Capital Healthcare Fund trims Vor Biopharma (NASDAQ: VOR) stake, still holds 3.9M shares - Stock Titan
VOR Forecast, Price Target & Analyst Ratings | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
Vor Biopharma (VOR) Financials 2026Income Statement and Balance Sheet $VOR - MarketBeat
Vor Biopharma (VOR) CMO discloses options and RSU-based stake - Stock Titan
Dow Update: What are analysts price targets for Vor Biopharma IncEarnings Recap Report & Precise Trade Entry Recommendations - baoquankhu1.vn
RA Capital (NASDAQ: VOR) discloses 19.9% Vor Biopharma ownership cap - Stock Titan
Vor Biopharma: It's A Game Of Wait And See (NASDAQ:VOR) - Seeking Alpha
Bull Bear: What are analysts price targets for Vor Biopharma IncMarket Risk Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Stifel reiterates Vor Biopharma stock rating on drug potential By Investing.com - Investing.com India
Stifel reiterates Vor Biopharma stock rating on drug potential - Investing.com
Vor Biopharma (VOR) Reiterated at Buy by Stifel After Meetings About Telitacicept Potential - StreetInsider
Aug Wrap: Should you buy the dip on Vor Biopharma Inc2026 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Aug Momentum: Is Vor Biopharma Inc currently under institutional pressure2026 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Vor Biopharma (NASDAQ:VOR) Shares Gap Down on Insider Selling - MarketBeat
Vor Biopharma(VOR.US) 10% Shareholder Sells US$14.52 Million in Common Stock - Moomoo
Ra capital sells Vor Biopharma (VOR) shares worth $14.5 million By Investing.com - Investing.com Canada
Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 260,000 Shares of Stock - MarketBeat
Ra capital sells Vor Biopharma (VOR) shares worth $14.5 million - Investing.com
RA Capital trims Vor Biopharma (VOR) stake with 849K-share sale - Stock Titan
Vor Biopharma (NASDAQ:VOR) Trading Down 5.8%Here's Why - marketbeat.com
Wall Street analysts predict a 107.82% upside in Vor Biopharma (VOR): Here's what you should know - MSN
Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 589,257 Shares of Stock - MarketBeat
Vor Biopharma (VOR) upgraded to buy: Here's why - MSN
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - MarketBeat
Jefferies initiates coverage of Vor Biopharma (VOR) with buy recommendation - MSN
Vor Biopharma (VOR) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street experts anticipate that Vor Biopharma (VOR) could surge by 107.82%: Key Information You Need to Know - bitget.com
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know - Yahoo Finance
Chen Yu and TCG entities hold 10.5% of Vor Biopharma (NASDAQ: VOR) - Stock Titan
TCG Crossover funds in Vor (VOR) disclose 2,836,539 common shares - Stock Titan
Vor Biopharma (VOR) ownership update shows RA Capital at 19.9% - Stock Titan
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Bio announces $75M private placement - MSN
Wedbush Maintains 'Neutral' Rating, Raises Price Target for Vor Biopharma (VOR) to $15 | VOR Stock News - gurufocus.com
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):